Text Size
Trial record 10 of 49 for:    hypoparathyroidism
Previous Study | Return to List | Next Study

Magnesium Treatment in Hypoparathyroidism

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vallo Volke, University of Tartu
ClinicalTrials.gov Identifier:
NCT00824226
First received: January 15, 2009
Last updated: August 26, 2011
Last verified: August 2011
History of Changes
  Purpose

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.


Condition Intervention
Hypoparathyroidism
 Dietary Supplement: magnesium

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients

Resource links provided by NLM:

MedlinePlus related topics: Calcium
Drug Information available for: Magnesium
U.S. FDA Resources

Further study details as provided by University of Tartu:

Primary Outcome Measures:
  • Calcium level at the end of magnesium treatment compared to pretreatment level [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Calcium level after stopping treatment compared to the level at the end of magnesium treatment [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: January 2009
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Dietary Supplement: magnesium
    magnesium 350 mg tablets once a day for 3 weeks
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • primary or secondary hypoparathyroidism
  • treatment with calcium plus vitamin D analogue
  • ionized calcium 1,0-1,29 mmol/L
  • magnesium level 0,7-1,05 mmol/L
  • TSH 0.1- 10 imU/L

Exclusion Criteria:

  • any other disease known to influence plasma Ca level
  • pregnancy
  • creatinine > 150 microM/L
  • patient has used supplementary magnesium within 2 previous months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00824226

Locations
Estonia
Tartu University Hospital
Tartu, Estonia, 50406
Sponsors and Collaborators
University of Tartu
Investigators
Principal Investigator: Vallo Volke, MD, PhD University of Tartu, Institute of Physiology
  More Information

No publications provided

Responsible Party: Vallo Volke, Dr., University of Tartu
ClinicalTrials.gov Identifier: NCT00824226     History of Changes
Other Study ID Numbers: UT296
Study First Received: January 15, 2009
Last Updated: August 26, 2011
Health Authority: Estonia: The State Agency of Medicine

Keywords provided by University of Tartu:
primary hypoparathyroidism
secondary hypoparathyroidism
magnesium

Additional relevant MeSH terms:
Hypoparathyroidism
Parathyroid Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 21, 2013